# GKOS — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-08-13. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 5.9 · Fundamentals 4.8 · Technicals 7 · Growth 7.5 · Risk 6

## Summary

GKOS shows strong technical momentum driven by recent earnings beat and guidance raise, but faces significant valuation challenges with negative margins and high debt. The stock is trading near 52-week highs with aggressive short interest, while analyst targets suggest upside potential above current price. Key catalysts include clinical progress on GLK-321 and market adoption of iStent inject stents.

## Price targets (3-month horizon)

- Bear: $146.55
- Base: $177.15
- Bull: $194.31

## News context

Recent news highlights record Q2 sales ($185.6M) and raised guidance to $680-700M, with analysts raising price targets up to $195 (HC Wainwright). Negative margins (-30.68%) and high debt (D/E 15.77) remain concerns. Insider selling by CFO Thurman Alex R. ($3.6M on Aug 7) signals internal caution despite strong technical momentum.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/gkos-ai-stock-forecast-34e1e5372283e262aa8be2b7b0e418cb
- AI-generated; model outputs can be wrong. Not financial advice.